Skip to main content

NASDAQ:REXN - Rexahn Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0.30 (1.20%)
Get New Rexahn Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for REXN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for REXN

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
This price target is based on 0 analysts offering 12 month price targets for Rexahn Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

N/A

The current consensus among 0 investment analysts is to n/a stock in Rexahn Pharmaceuticals. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/16/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/7/2019Ifs SecuritiesDowngradeStrong-Buy ➝ Market PerformHigh
i
Rating by D. Bouchey at Ifs Securities
8/7/2019HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by J. Pantginis at HC Wainwright
4/17/2019HC WainwrightSet Price TargetBuy$23.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
3/8/2019HC WainwrightReiterated RatingBuy$120.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
2/5/2019HC WainwrightLower Price TargetBuy$120.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
1/15/2019HC WainwrightReiterated RatingBuy$204.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
12/6/2018HC WainwrightSet Price TargetBuy$204.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
11/27/2018Brookline Capital ManagementReiterated RatingBuyN/A
i
Rating by K. Raja at Brookline Capital Management
11/5/2018HC WainwrightSet Price TargetBuy$204.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
10/4/2018Ifs SecuritiesUpgradeOutperform ➝ Strong-BuyMedium
i
Rating by D. Bouchey at Ifs Securities
10/2/2018B. RileySet Price TargetBuy$96.00N/A
i
Rating by George Zavoico at B. Riley
10/2/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
9/25/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
8/13/2018B. RileySet Price TargetBuy$96.00N/A
i
Rating by George Zavoico at B. Riley
8/6/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
7/31/2018B. RileyReiterated RatingBuyLow
i
Rating by G. Zavoico at B. Riley
7/31/2018B. RileyInitiated CoverageBuy$90.00N/A
i
Rating by G. Zavoico at B. Riley
6/4/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
5/15/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
5/7/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
3/12/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
2/12/2018HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by Joseph Pantginis at HC Wainwright
1/22/2018HC WainwrightReiterated RatingBuy$234.00N/A
i
11/6/2017HC WainwrightReiterated RatingBuy$234.00N/A
i
Rating by J. Pantginis at HC Wainwright
10/6/2017Seaport Global SecuritiesReiterated RatingBuy$156.00N/A
i
Rating by V. Bernardino at Seaport Global Securities
9/11/2017HC WainwrightSet Price TargetBuy$240.00N/A
i
Rating by J. Pantginis at HC Wainwright
8/14/2017HC WainwrightReiterated RatingBuy$240.00N/A
i
Rating by J. Pantginis at HC Wainwright
8/7/2017Ifs SecuritiesReiterated RatingOutperformN/A
i
Rating by D. Bouchey at Ifs Securities
6/9/2017Rodman & RenshawReiterated RatingBuy$234.00N/A
i
6/1/2017(FBRC)Reiterated RatingOutperform$360.00 ➝ $168.00N/A
i
5/26/2017(FBRC)Set Price TargetBuy$168.00N/A
i
5/22/2017HC WainwrightReiterated RatingBuy$234.00N/A
i
4/6/2017HC WainwrightSet Price TargetBuy$24.00N/A
i
4/6/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$24.00N/A
i
2/27/2017(FBRC)Reiterated RatingOutperform$36.00N/A
i
1/24/2017(FBRC)Reiterated RatingOutperformN/A
i
10/13/2016(FBRC)Reiterated RatingOutperform$36.00N/A
i
10/5/2016(FBRC)Reiterated RatingOutperform$36.00N/A
i
(Data available from 5/16/2016 forward)
Rexahn Pharmaceuticals logo
Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $2.06
$1.81
$2.24

52 Week Range

Now: N/A

Volume

2,579 shs

Average Volume

162,968 shs

Market Capitalization

$8.11 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.98

Frequently Asked Questions

What sell-side analysts currently cover shares of Rexahn Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Rexahn Pharmaceuticals in the last year:
View the latest analyst ratings for REXN.

What is the current price target for Rexahn Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Rexahn Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Rexahn Pharmaceuticals in the next year.
View the latest price targets for REXN.

What is the current consensus analyst rating for Rexahn Pharmaceuticals?

Rexahn Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for REXN.

What other companies compete with Rexahn Pharmaceuticals?

How do I contact Rexahn Pharmaceuticals' investor relations team?

Rexahn Pharmaceuticals' physical mailing address is 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD, 20850. The company's listed phone number is (248) 681-9815 and its investor relations email address is [email protected] The official website for Rexahn Pharmaceuticals is www.rexahn.com.